Alpha 2.0
Login Register
» Articles » PMID: 33606005

Chimeric Antigen Receptor T-cell Therapy in Multiple Myeloma: a Systematic Review and Meta-analysis of 950 Patients

Overview
Journal Blood Adv
Specialty Hematology
Date 2021 Feb 19
PMID 33606005
Citations 11
Authors
Ghulam Rehman Mohyuddin
Anthony Rooney
Nicole Balmaceda
Muhammad Aziz
Douglas W Sborov
Brian McClune
Shaji K Kumar
Affiliations
Soon will be listed here.
Citing Articles

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.

Abramson H Int J Mol Sci. 2023; 24(21).

PMID: 37958658 PMC: 10649824. DOI: 10.3390/ijms242115674.

Fitness and frailty in myeloma.

Pawlyn C, Khan A, Freeman C Hematology Am Soc Hematol Educ Program. 2022; 2022(1):337-348.

PMID: 36485137 PMC: 9820647. DOI: 10.1182/hematology.2022000346.

Progress on CAR-T cell therapy for hematological malignancies.

Hu K, Huang Y, Hu Y, Huang H Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022; 51(2):192-203.

PMID: 36161291 PMC: 9353627. DOI: 10.3724/zdxbyxb-2022-0055.

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.

Lebel E, Nachmias B, Pick M, Even-Zohar N, Gatt M J Clin Med. 2022; 11(7).

PMID: 35407416 PMC: 9000075. DOI: 10.3390/jcm11071809.

Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma.

Wei Y, Wang J, Chen F, Li X, Zhang J, Shen M Front Oncol. 2022; 12:808290.

PMID: 35296015 PMC: 8919723. DOI: 10.3389/fonc.2022.808290.

References
1.
Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View
2.
Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y . A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019; 6(10):e521-e529. DOI: 10.1016/S2352-3026(19)30115-2. View
3.
Cohen A, Garfall A, Stadtmauer E, Melenhorst J, Lacey S, Lancaster E . B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019; 129(6):2210-2221. PMC: 6546468. DOI: 10.1172/JCI126397. View
4.
Brudno J, Maric I, Hartman S, Rose J, Wang M, Lam N . T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J Clin Oncol. 2018; 36(22):2267-2280. PMC: 6067798. DOI: 10.1200/JCO.2018.77.8084. View
5.
Rajkumar S . Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020; 95(5):548-567. DOI: 10.1002/ajh.25791. View